We are live on ! Find out more
PTGX icon

Protagonist Therapeutics

189 hedge funds and large institutions have $2.05B invested in Protagonist Therapeutics in 2024 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 63 increasing their positions, 69 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more funds holding in top 10

Funds holding in top 10: 6 → 8 (+2)

20% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 25

2% more funds holding

Funds holding: 185 → 189 (+4)

9% less repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 69

2.2% less ownership

Funds ownership: 102.93% → 100.73% (-2.2%)

11% less capital inflows, than outflows

Capital inflows: $206M | Capital outflows: $230M

87% less call options, than puts

Call options by funds: $956K | Put options by funds: $7.56M

Holders
189
Holders Change
+4
Holders Change %
+2.16%
% of All Funds
2.72%
Holding in Top 10
8
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+33.33%
% of All Funds
0.12%
New
30
Increased
63
Reduced
69
Closed
25
Calls
$956K
Puts
$7.56M
Net Calls
-$6.61M
Net Calls Change
-$894K

PTGX Hedge Fund Activity: Q2 2024 in Review

189 of the 6,946 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q2 2024, worth a combined $2.05B — up 18% from $1.74B a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new PTGX positions and 25 closed out — a net gain of 5 holders — while 63 added to existing stakes and 69 trimmed.

The largest buyer was Millennium Management, adding an estimated $26.8M. The largest seller was Morgan Stanley, cutting an estimated $44.9M.

  • 189 institutional investors held Protagonist Therapeutics (PTGX) as of Q2 2024, up from 185 in Q1 2024.
  • Funds reported $2.05B of Protagonist Therapeutics stock for Q2 2024, up 18% quarter-over-quarter.
  • 30 funds opened new Protagonist Therapeutics positions in Q2 2024 and 25 closed out, a net change of +5 holders.
  • The largest Protagonist Therapeutics buyer in Q2 2024 was Millennium Management, an estimated $26.8M added.
  • The largest Protagonist Therapeutics seller in Q2 2024 was Morgan Stanley, an estimated $44.9M sold.

Based on aggregated 13F filings for Q2 2024.